2021
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljkovic M, Horvath TL, Hajós M. Therapy for Alzheimer’s disease: Missing targets and functional markers? Ageing Research Reviews 2021, 68: 101318. PMID: 33711510, PMCID: PMC8131215, DOI: 10.1016/j.arr.2021.101318.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseNew symptomatic treatmentsNeural network integrityClinical characteristicsNext-generation therapiesSymptomatic treatmentOutcome biomarkerTau pathologyFluid biomarkersPlasma biomarkersDisease progressionEffective therapyNeurophysiological biomarkersTreatment candidatesCerebrospinal fluidNovel biomarkersTranslational studiesTreatment interventionsDiseaseTarget engagementTherapyBiomarkersCurrent conceptsMultiple biomarkersDrug targets
2015
Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy
Nagy D, Stoiljkovic M, Menniti FS, Hajós M. Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy. Neuropsychopharmacology 2015, 41: 1486-1494. PMID: 26404843, PMCID: PMC4832008, DOI: 10.1038/npp.2015.298.Peer-Reviewed Original ResearchConceptsAuditory-evoked potentialsAntidepressant effectsSynaptic potentiationAntidepressant efficacyAuditory gatingRapid-onset antidepressant effectsEffects of ketaminePrimary auditory cortexReceptor channel blockerDifferent acute effectsNMDA receptor inhibitionNegative allosteric modulatorsPotential mechanistic underpinningsReceptor inhibitionSystemic administrationAcute effectsNeurophysiological biomarkersTranslatable biomarkersChannel blockersDrug eliminationAuditory cortexNeurophysiological parametersDrug AdministrationGamma band powerKetamine
2014
Application of neurophysiological biomarkers for Huntington's disease: Evaluating a phosphodiesterase 9A inhibitor
Nagy D, Tingley FD, Stoiljkovic M, Hajós M. Application of neurophysiological biomarkers for Huntington's disease: Evaluating a phosphodiesterase 9A inhibitor. Experimental Neurology 2014, 263: 122-131. PMID: 25315303, DOI: 10.1016/j.expneurol.2014.10.001.Peer-Reviewed Original ResearchMeSH Keywords3',5'-Cyclic-AMP PhosphodiesterasesAcoustic StimulationAnimalsAuditory CortexDisease Models, AnimalElectrophysiologyEnzyme InhibitorsEvoked Potentials, AuditoryHippocampusHuntington DiseaseMiceMice, Inbred C57BLMice, TransgenicPyrazolesPyrimidinonesRatsRats, Sprague-DawleyRats, TransgenicSensory GatingConceptsBACHD transgenic ratsPrimary auditory cortexAuditory gatingDisease patientsHuntington's diseaseAuditory cortexBACHD ratsTransgenic ratsPF-04447943Sub-chronic treatmentPotential translational biomarkersHuntington's disease patientsTransgenic animal modelsBasic neuropathologyDaily administrationTranslational biomarkersQ175 miceNeurophysiological abnormalitiesSystemic administrationNeurophysiological biomarkersLast treatmentAnimal modelsTransgenic miceGamma band powerBrain regions